68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients

Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):689-694. doi: 10.1007/s00259-016-3563-6. Epub 2016 Nov 8.

Abstract

Background: To report on imaging findings using 68Ga-PSMA-HBED-CC PET in a series of 19 breast carcinoma patients.

Methods: 68Ga-PSMA-HBED-CC PET imaging results obtained were compared to routinely performed staging examinations and analyzed as to lesion location and progesterone receptor status.

Results: Out of 81 tumor lesions identified, 84% were identified on 68Ga-PSMA-HBED-CC PET. 68Ga-PSMA-HBED-CC SUVmean values of distant metastases proved significantly higher (mean, 6.86, SD, 5.68) when compared to those of primary or local recurrences (mean, 2.45, SD, 2.55, p = 0.04) or involved lymph nodes (mean, 3.18, SD, 1.79, p = 0.011). SUVmean values of progesterone receptor-positive lesions proved not significantly different from progesterone receptor-negative lesions. SUV values derived from FDG PET/CT, available in seven patients, and 68Ga-PSMA-HBED-CC PET/CT imaging proved weakly correlated (r = 0.407, p = 0.015).

Conclusions: 68Ga-PSMA-HBED-CC PET/CT imaging in breast carcinoma confirms the reported considerable variation of PSMA expression on human solid tumors using immunohistochemistry.

Keywords: 68Ga-PSMA; Breast cancer; PET/CT.

Publication types

  • Comparative Study
  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Breast Neoplasms / diagnostic imaging*
  • Carcinoma / diagnostic imaging*
  • Edetic Acid / analogs & derivatives
  • Female
  • Fluorodeoxyglucose F18
  • Gallium Isotopes
  • Gallium Radioisotopes
  • Humans
  • Middle Aged
  • Oligopeptides
  • Organometallic Compounds*
  • Positron Emission Tomography Computed Tomography*
  • Radiopharmaceuticals*

Substances

  • Gallium Isotopes
  • Gallium Radioisotopes
  • Oligopeptides
  • Organometallic Compounds
  • Radiopharmaceuticals
  • gallium 68 PSMA-11
  • Fluorodeoxyglucose F18
  • Edetic Acid